ProShare Advisors
INZY

ProShare Advisors’s Inozyme Pharma INZY Stock Holding History

ProShare Advisors’s Portfolio INZY Stock Details INZY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-14,521
Closed -$13.2K – 2128
2025
Q1 		$13.2K Sell
14,521
-3,286
-18% -$4.55K ﹤0.01% 2059
2024
Q4 		$49.3K Buy
+17,807
New +$67.7K ﹤0.01% 2178

Other funds holding INZY

BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.54B AUM 41.83% 1-Year Est. Return
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

ProShare Advisors's INZY Position: Q2 2025 in Review

ProShare Advisors sold out of Inozyme Pharma (INZY) in Q2 2025, closing a stake of 14,521 shares — an estimated $13.2K sold.

ProShare Advisors first reported a position in INZY in Q4 2024 and held it in 2 quarters. The position peaked at $49.3K in Q4 2024. 86 funds tracked by Wall St. Rank hold INZY as of Q2 2025.

  • ProShare Advisors reported no remaining Inozyme Pharma position as of Q2 2025 after selling out during the quarter.
  • ProShare Advisors sold 14,521 Inozyme Pharma shares in Q2 2025, an estimated $13.2K.
  • ProShare Advisors first reported a position in Inozyme Pharma in Q4 2024 and held it in 2 quarters.
  • ProShare Advisors's Inozyme Pharma position peaked at $49.3K in Q4 2024.
  • 86 funds tracked by Wall St. Rank held Inozyme Pharma as of Q2 2025.

Based on ProShare Advisors's 13F filing for Q2 2025, filed 7 Aug 2025.